SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
December 20, 2004
HEMISPHERX BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-27072 52-0845822
(state or other juris- (Commission (I.R.S. Employer
diction of incorporation) File Number) (Identification No.)
1617 JFK Boulevard, Philadelphia, Pennsylvania 19103
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (215) 988-0080
(Former name or former address, if changed since last report)
ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE
As agreed with the Company at the outset of becoming a director, having
served for a period of 1 year, Dr. Antoni Esteve has resigned as a director.
Dr. Esteve will continue to meet with top management of the Company on an
ongoing basis with regard to its developmental drug Ampligen, with particular
focus on the HIV/HCV clinical trial using Ampligen being conducted in Spain by
Laboratorios del Dr. Esteve, S.A. in collaboration with the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
HEMISPHERX BIOPHARMA, INC.
December 20, 2004 By: /s/William A. Carter
----------------------------
William A. Carter, M.D.,
President